Los Angeles Capital Management
TVRD

Los Angeles Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Los Angeles Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,505
Closed -$582K – 1320
2022
Q4 		$582K Sell
1,505
-1,146
-43% -$435K ﹤0.01% 852
2022
Q3 		$893K Buy
2,651
+752
+40% +$272K ﹤0.01% 741
2022
Q2 		$624K Buy
+1,899
New +$666K ﹤0.01% 887

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's TVRD Position: Q1 2023 in Review

Los Angeles Capital Management sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 1,505 shares — an estimated $582K sold.

Los Angeles Capital Management first reported a position in TVRD in Q2 2022 and held it in 3 quarters. The position peaked at $893K in Q3 2022. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Los Angeles Capital Management reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Los Angeles Capital Management sold 1,505 Tvardi Therapeutics shares in Q1 2023, an estimated $582K.
  • Los Angeles Capital Management first reported a position in Tvardi Therapeutics in Q2 2022 and held it in 3 quarters.
  • Los Angeles Capital Management's Tvardi Therapeutics position peaked at $893K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.